1. Search Result
Search Result
Results for "

BV-2 microglia

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

12

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0442

    4'-O-β-D-Glucosyl-5-O-methylvisamminol

    NF-κB p38 MAPK JNK Src TNF Receptor NOD-like Receptor (NLR) Amyloid-β MEK ERK Ferroptosis VEGFR Anaplastic lymphoma kinase (ALK) Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway .
    5-O-Methylvisammioside
  • HY-19667A
    BMS-561392 formate
    2 Publications Verification

    DPC 333 formate

    TNF Receptor NF-κB Apoptosis p38 MAPK Neurological Disease Inflammation/Immunology
    BMS-561392 formate (DPC 333 formate) is a selective ADAM17(TACE) inhibitor. BMS-561392 formate inhibits TNF-α secretion by regulating signaling pathways such as p44 MAPK and NF-κB. BMS-561392 formate also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 formate promotes microglial apoptosis, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 formate can be used in research related to spinal cord injury and inflammatory diseases .
    BMS-561392 formate
  • HY-107581
    MK-1903
    1 Publications Verification

    GPR109A MMP Metabolic Disease Inflammation/Immunology
    MK-1903 is an orally active full agonist of GPR109a/HCAR2, with an EC50 of 12.9 nM. MK-1903 activates antilipolytic and vasodilatory pathways, reduces plasma free fatty acid levels, and induces skin flushing. MK-1903 stimulates the expression of HCAR2 protein and regulates the inflammatory response of microglia. MK-1903 prevents the enhanced firing activity of spinal nociceptive neurons. MK-1903 triggers the release of MMP-9 and the formation of NET. MK-1903 can be used in the research of dyslipidemia and neuroinflammation-based central nervous system diseases .
    MK-1903
  • HY-19667

    DPC 333

    TNF Receptor NF-κB Apoptosis p38 MAPK Neurological Disease Inflammation/Immunology
    BMS-561392 (BMS-561392) is a selective ADAM17(TACE) inhibitor. BMS-561392 inhibits TNF-α secretion by regulating signaling pathways such as p44 MAPK and NF-κB. BMS-561392 also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 promotes microglial apoptosis, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 can be used in research related to spinal cord injury and inflammatory diseases .
    BMS-561392
  • HY-164049

    Prostaglandin Receptor Inflammation/Immunology
    TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .
    TG8-260
  • HY-N3915

    NO Synthase Neurological Disease Inflammation/Immunology
    Futoquinol is a neolignan isolated from the dried aerial parts of Piper kadsura (Piperaceae). Futoquinol potently inhibits NO production in microglia cells. Futoquinol has anti-neuroinflammatory activities .
    Futoquinol
  • HY-N8090

    NO Synthase Inflammation/Immunology
    (3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid, a lanostane triterpenoids, exhibits obvious NO inhibitory activity on n LPS-induced BV-2 microglia cells with an IC50 of 9.55 uM. (3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid has anti-inflammatory activities .
    (3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid
  • HY-N10386

    Others Inflammation/Immunology
    Dichotomine B, a β-Carboline alkaloid, attenuates neuroinflammatory responses in LPS/ATP-induced BV2 microglia .
    Dichotomine B
  • HY-119465

    Fungal Others
    Restricticin is a compound obtained from marine fungi, whose structure contains alkene, tetrahydropyran ring and glycine ester functional groups, and has anti-neuroinflammatory effects in lipopolysaccharide-induced BV-2 microglia by inhibiting the production of proinflammatory mediators.
    Restricticin
  • HY-N9675

    NO Synthase Inflammation/Immunology
    (+)-Hannokinol can be isolated from AMOMUM TSAO-KO (ginger family) fruit. (+)-Hannokinol inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglia .
    (+)-Hannokinol
  • HY-155762

    NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype .
    Anti-neuroinflammation agent 1
  • HY-N7018

    Others Inflammation/Immunology
    20-Hydroxyganoderic Acid G is a lanostane triterpenoid obtained from the EtOH extract of fruiting bodies of the Ganoderma curtisii. 20-Hydroxyganoderic Acid G inhibits BV-2 microglia cells activated by LPS with an IC50 of 21.33 μM. 20-Hydroxyganoderic Acid G has therapeutic potential in the agent discovery of nerve inflammation diseases associated with microglia activated by LPS .
    20-Hydroxyganoderic Acid G
  • HY-N0859B

    NO Synthase Neurological Disease
    Schisanchinin D is an NO release inhibitor found in the fruits of Schisandra chinensis. Schisanchinin D can inhibit the release of nitric oxide (NO) by lipopolysaccharide (LPS)-activated microglia in primary murine BV2 microglia cells. Schisanchinin D is promising for research of neurodegenerative diseases such as Alzheimer's disease (AD) .
    Schisanchinin D
  • HY-N3814

    Others Inflammation/Immunology
    ent-16β,17-Dihydroxykauran-19-oic acid is an anti-inflammatory agent, which can be isolated from Siegesbeckia pubescens herb. ent-16β,17-Dihydroxykauran-19-oic acid inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglia .
    ent-16β,17-Dihydroxykauran-19-oic acid
  • HY-N10458

    NF-κB Inflammation/Immunology
    Asperbisabolane L, a sesquiterpenoid, exerts the anti-inflammatory activity by inhibiting the NF-κB-activated pathway. Asperbisabolane L inhibits the translocation of NF-κB from cytoplasm to the nucleus. Asperbisabolane L also inhibits NO production in LPS-activated BV-2 microglia cells .
    Asperbisabolane L
  • HY-N13729

    NO Synthase Cardiovascular Disease Neurological Disease
    Stephalonine P is a hasubanan-type alkaloid anti-inflammatory agent with neuroprotective effects against neuroinflammation. Stephalonine P regulates post-ischemic inflammatory responses by inhibiting NO production in LPS-activated BV2 microglia (IC50=34.01 μM), thereby reducing microglial activation and neuronal damage. Stephalonine P can be isolated from the whole plant of Stephania japonica. Stephalonine P can be used in research on stroke and other neuroinflammation-related diseases .
    Stephalonine P
  • HY-180889

    PROTACs Epigenetic Reader Domain Neurological Disease Inflammation/Immunology
    PROTAC BRD3 degrader-1 (compound D072) is a potent and selective PROTAC BRD3 degrader. PROTAC BRD3 degrader-1 selectively degrades BRD3 in mice, leading to the downregulation of H3K18ac without affecting BRD2 or BRD4. PROTAC BRD3 degrader-1 reduces intraocular inflammation in the experimental autoimmune uveitis (EAU) mouse mode and inhibits proinflammatory microglia in both uveitis retina and LPS (HY-D1056) treated mouse microglia cell line BV2. PROTAC BRD3 degrader-1 can be used for uveitis research .
    PROTAC BRD3 degrader-1
  • HY-181818

    Keap1-Nrf2 NO Synthase TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    4,5-Dehydro-6-oxoallosecurinine is a Keap1-Nrf2 pathway activator. 4,5-Dehydro-6-oxoallosecurinine promotes the nuclear translocation of Keap1-Nrf2, and induces the expression of antioxidant and cytoprotective genes. 4,5-Dehydro-6-oxoallosecurinine reduces the production of NO, and decreases the levels of iNOS, TNF-α, IL-6 and IL-1β in LPS-stimulated microglia. 4,5-Dehydro-6-oxoallosecurinine can be used for the research of neurodegenerative diseases .
    4,5-Dehydro-6-oxoallosecurinine
  • HY-N17562

    NO Synthase Interleukin Related IKK NF-κB Inflammation/Immunology
    Acutissimalignan B is a natural product. Acutissimalignan B can be isolated from Daphne kiusiana var. atrocaulis (Rehd.) F. Maekawa. Acutissimalignan B can reduce the mRNA expression of inflammatory cytokines (iNOS, TNF-α, IL-1β, and IL-6), inhibit the phosphorylation of IκBα, and inhibit the nuclear translocation of NK-κB p65. Acutissimalignan B shows anti-neuroinflammatory effects .
    Acutissimalignan B
  • HY-179646

    Toll-like Receptor (TLR) NO Synthase NF-κB TNF Receptor Interleukin Related Neurological Disease
    CIAC101 is a potent and brain-penetrant TLR4 antagonist with an IC50 of 17.0 nM in NO assay. CIAC101 blocks Lipopolysaccharides (HY-D1056) (LPS)-induced NF-κB activation and reduces the expression of pro-inflammatory mediators (iNOS, IL-1β, TNF-α, and IL-6). CIAC101 robust antineuroinflammatory activity with efficacy against drug-evoked neurobehavioral adaptations. CIAC101 can be used for the research of addiction and neurological disease .
    CIAC101

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: